PMID- 36865057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230304
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Do intravitreal anti-vascular endothelial growth factor agents lead to renal 
      adverse events? A pharmacovigilance real-world study.
PG  - 1100397
LID - 10.3389/fmed.2023.1100397 [doi]
LID - 1100397
AB  - PURPOSE: Intravitreal vascular endothelial growth factor (VEGF) blockade is 
      essential in many macular edema diseases treatment. However, intravitreal VEGF 
      treatment has been reported to lead to deteriorated proteinuria and renal 
      function. This study aimed to explore the relationship between renal adverse 
      events (AEs) and the intravitreal use of VEGF inhibitors. METHOD: In the FDA's 
      Adverse Event Reporting System (FAERS) database, we searched for renal AEs of 
      patients receiving various anti-VEGF drugs. We performed statistics on renal AEs 
      in patients treated with Aflibercept, Bevacizumab, Ranibizumab, and Brolucizumab 
      (from January 2004 to September 2022) using disproportionate and Bayesian 
      analysis. We also investigated the time to onset, fatality, and hospitalization 
      rates of renal AEs. RESULTS: We identified 80 reports. Renal AEs were most 
      frequently associated with Ranibizumab (46.25%) and Aflibercept (42.50%). 
      However, the association between intravitreal anti-VEGFs and renal AEs was 
      insignificant since the reporting odds ratio of Aflibercept, Bevacizumab, 
      Ranibizumab, and Brolucizumab were 0.23 (0.16, 0.32), 0.24 (0.11, 0.49), 0.37 
      (0.27, 0.51) and 0.15 (0.04, 0.61), respectively. The median time to renal AEs 
      onsets was 37.5 (interquartile range 11.0-107.3) days. The hospitalization and 
      fatality rates in patients who developed renal AEs were 40.24 and 9.76%, 
      respectively. CONCLUSION: There are no clear signals for the risk of renal AEs 
      following various intravitreal anti-VEGF drugs based on FARES data.
CI  - Copyright (c) 2023 Jiang, Peng, Zhou, Chen, Zhao, Li and Li.
FAU - Jiang, Lin
AU  - Jiang L
AD  - Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical 
      College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Peng, Liying
AU  - Peng L
AD  - Nephrology Department, Peking Union Medical College Hospital, Peking Union 
      Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Zhou, Yangzhong
AU  - Zhou Y
AD  - Nephrology Department, Peking Union Medical College Hospital, Peking Union 
      Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Chen, Gang
AU  - Chen G
AD  - Nephrology Department, Peking Union Medical College Hospital, Peking Union 
      Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Zhao, Bin
AU  - Zhao B
AD  - Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical 
      College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Li, Mingxi
AU  - Li M
AD  - Nephrology Department, Peking Union Medical College Hospital, Peking Union 
      Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Li, Xuemei
AU  - Li X
AD  - Nephrology Department, Peking Union Medical College Hospital, Peking Union 
      Medical College, Chinese Academy of Medical Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20230214
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9972674
OTO - NOTNLM
OT  - acute kidney injury
OT  - adverse event reporting system
OT  - ophthalmic medicine
OT  - pharmacovigilance
OT  - vascular endothelial growth factor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/04 06:00
MHDA- 2023/03/04 06:01
PMCR- 2023/02/14
CRDT- 2023/03/03 02:27
PHST- 2022/11/16 00:00 [received]
PHST- 2023/01/17 00:00 [accepted]
PHST- 2023/03/03 02:27 [entrez]
PHST- 2023/03/04 06:00 [pubmed]
PHST- 2023/03/04 06:01 [medline]
PHST- 2023/02/14 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1100397 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Feb 14;10:1100397. doi: 10.3389/fmed.2023.1100397. 
      eCollection 2023.